Buspirone transdermal - Bristol-Myers Squibb/Elan

Drug Profile

Buspirone transdermal - Bristol-Myers Squibb/Elan

Alternative Names: BuSpar Patch

Latest Information Update: 18 Jun 2001

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Bristol-Myers Squibb
  • Class Antidepressants; Anxiolytics; Pyrimidines; Small molecules; Spiro compounds
  • Mechanism of Action Serotonin 1A receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Anxiety disorders; Attention-deficit hyperactivity disorder; Major depressive disorder

Most Recent Events

  • 18 Jun 2001 Discontinued-III for Anxiety disorders in USA (Transdermal)
  • 18 Jun 2001 Discontinued-III for Anxiety disorders in Western Europe (Transdermal)
  • 18 Jun 2001 Discontinued-III for Attention-deficit hyperactivity disorder in USA (Transdermal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top